The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...
Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...
By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback